Clinical trial
A Phase 1, Partially-Blinded, Placebo-Controlled, Randomized, Single Ascending Dose (SAD) With a Food Effect Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adult Participants.
NCT03758612 is registered in ClinicalTrials.gov with Global Alliance for TB Drug Development as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Partially-Blinded, Placebo-Controlled, Randomized, Single Ascending Dose (SAD) With a Food Effect Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adult Participants.
- Lead sponsor
- Global Alliance for TB Drug Development
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 16, 2019
- Completion date
- March 15, 2020
- Enrollment
- 86 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.